Dirk Reyn

Dirk Reyn

Dirk Reyn

chairman of the board - flanders.bio

Dirk Reyn is a Pharmacist/MBA with more than 30 years’ experience in the life science industry. He is currently Managing Partner of BioQube Ventures (2015). Dirk has gained commercial experience at Eli Lilly and Janssen-Cilag (Johnson & Johnson). In 2006, Dirk co-founded Movetis NV, a JNJ spin-off for GI assets. As CEO, he was instrumental in building this company, getting Resolor (a prokinetic) approved in 2009 for chronic constipation and launched in four countries with reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Since then he has co-founded Progress Pharma (2013), Lipid Therapeutics (2015) and eTheRNA, a spin-off from the University of Brussels with a breakthrough mRNA-based immunotherapy for cancer & infectious diseases (2016), Across Health (2017, Chairman of the board) and Spectricity, (2018, an Imec spin-off). Since 2013 Dirk is part of the Board of Directors of flanders.bio.

 

MEET DIRK REYN @ #KFG2019
Dirk Reyn will be your host for the closing plenary session. 

REGISTER NOW

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners